Search

Your search keyword '"Luu Hong Dang Nguyen"' showing total 3 results
Start Over Author "Luu Hong Dang Nguyen"
3 results on '"Luu Hong Dang Nguyen"'

1. A consultation and work-up diagnosis protocol for a multicancer early detection test: a case series study

Author

Luu Hong Dang Nguyen, Ba Linh Tieu, Thi Thanh Nguyen, Nhung Phuong Ha, Giang Thi Huong Nguyen, Thi Hue Hanh Nguyen, Van Hoi Le, Vinh Quang Bui, Lan Hieu Nguyen, Nhu Hiep Pham, Thanh Hai Phan, Huu Thinh Nguyen, Van Song Tran, Chi Viet Bui, Van Kha Vo, Pham Thanh Nhan Nguyen, Ha Huu Phuoc Dang, Van Dung Pham, Van Thinh Cao, Ngoc Minh Phan, Van Tung Nguyen, Thi Le Quyen Le, Thi Lan-Anh Luong, Thi Kim Phuong Doan, Canh Duy Phan, Thanh Xuan Nguyen, Nguyen Tuong Pham, Bao Toan Nguyen, Thi Thu Thuy Pham, Huu Linh Le, Cong Thanh Truong, Thanh Xuan Jasmine, Minh Chi Le, Van Bau Phan, Quang Binh Truong, Thi Huong Ly Tran, Minh Thien Huynh, Tu Quy Tran, Si Tuan Nguyen, Vu Tran, Van Khanh Tran, Huu Nguyen Nguyen, Thi Van Phan, Thi Thanh-Thuy Do, Dinh Kiet Truong, Hoa Giang, Hoai-Nghia Nguyen, Minh-Duy Phan, Le Son Tran, Hung Sang Tang, and Duy Sinh Nguyen

Subjects
case reports, consultation, ctDNA, MCED, SPOT-MAS, work-up diagnosis, Medicine, Medicine (General), R5-920
Abstract

The emergence of multicancer early detection (MCED) tests holds promise for improving early cancer detection and public health outcomes. However, positive MCED test results require confirmation through recommended cancer diagnostic imaging modalities. To address these challenges, we have developed a consultation and work-up protocol for definitive diagnostic results post MCED testing, named SPOT-MAS. Developed through circulating tumor DNA (ctDNA) analysis and in line with professional guidelines and advisory board consensus, this protocol standardizes information to aid general practitioners in accessing, interpreting and managing SPOT-MAS results. Clinical effectiveness is demonstrated through a series of identified cancer cases. Our research indicates that the protocol could empower healthcare professionals to confidently interpret circulating tumor DNA test results for 5 common types of cancer, thereby facilitating the clinical integration of MCED tests.

Published
2024
Full Text
View/download PDF

2. Clinical validation of a ctDNA-Based Assay for Multi-Cancer Detection: An Interim Report from a Vietnamese Longitudinal Prospective Cohort Study of 2795 Participants

Author

Thi Hue Hanh Nguyen, Y-Thanh Lu, Van Hoi Le, Vinh Quang Bui, Lan Hieu Nguyen, Nhu Hiep Pham, Thanh Hai Phan, Huu Thinh Nguyen, Van Song Tran, Chi Viet Bui, Van Kha Vo, Pham Thanh Nhan Nguyen, Ha Huu Phuoc Dang, Van Dung Pham, Van Thinh Cao, Thanh Dat Nguyen, Luu Hong Dang Nguyen, Ngoc Minh Phan, Trong Hieu Nguyen, Van Thien Chi Nguyen, Thi Mong Quynh Pham, Vu Uyen Tran, Minh Phong Le, Dac Ho Vo, Thi Minh Thu Tran, Minh Nguyen Nguyen, Thi Thanh Nguyen, Ba Linh Tieu, Huu Tam Phuc Nguyen, Dinh Yen An Truong, Chi Thuy Tien Cao, Van Tung Nguyen, Thi Le Quyen Le, Thi Lan Anh Luong, Thi Kim Phuong Doan, Thi Trang Dao, Canh Duy Phan, Thanh Xuan Nguyen, Nguyen Tuong Pham, Bao Toan Nguyen, Thi Thu Thuy Pham, Huu Linh Le, Cong Thanh Truong, Thanh Xuan Jasmine, Minh Chi Le, Van Bau Phan, Quang Binh Truong, Thi Huong Ly Tran, Minh Thien Huynh, Tu Quy Tran, Si Tuan Nguyen, Vu Tran, Van Khanh Tran, Huu Nguyen Nguyen, Duy Sinh Nguyen, Thi Quynh Tho Nguyen, Thi Van Phan, Thi Thanh-Thuy Do, Dinh-Kiet Truong, Hung Sang Tang, Minh Duy Phan, Hoa Giang, Hoai Nghia Nguyen, and Le Son Tran

Subjects
Cancer Research, Oncology, General Medicine
Abstract

The SPOT-MAS assay “Screening for the Presence Of Tumor by Methylation And Size” detects the five most common cancers in Vietnam by evaluating circulating tumor DNA in the blood. Here, we validated its performance in a prospective multi-center clinical trial, K-DETEK. Our analysis of 2795 participants from 14 sites across Vietnam demonstrates its ability to detect cancers in asymptomatic individuals with a positive predictive value of 60%, with 83.3% accuracy in detecting tumor location. We present a case report to support further using SPOT-MAS as a complementary method to achieve early cancer detection and provide the opportunity for early treatment.

Published
2023
Full Text
View/download PDF

3. Multimodal analysis of methylomics and fragmentomics in plasma cell-free DNA for multi-cancer early detection and localization

Author

Van Thien Chi Nguyen, Trong Hieu Nguyen, Nhu Nhat Tan Doan, Thi Mong Quynh Pham, Giang Thi Huong Nguyen, Thanh Dat Nguyen, Thuy Thi Thu Tran, Duy Long Vo, Thanh Hai Phan, Thanh Xuan Jasmine, Van Chu Nguyen, Huu Thinh Nguyen, Trieu Vu Nguyen, Thi Hue Hanh Nguyen, Le Anh Khoa Huynh, Trung Hieu Tran, Quang Thong Dang, Thuy Nguyen Doan, Anh Minh Tran, Viet Hai Nguyen, Vu Tuan Anh Nguyen, Le Minh Quoc Ho, Quang Dat Tran, Thi Thu Thuy Pham, Tan Dat Ho, Bao Toan Nguyen, Thanh Nhan Vo Nguyen, Thanh Dang Nguyen, Dung Thai Bieu Phu, Boi Hoan Huu Phan, Thi Loan Vo, Thi Huong Thoang Nai, Thuy Trang Tran, My Hoang Truong, Ngan Chau Tran, Trung Kien Le, Thanh Huong Thi Tran, Minh Long Duong, Hoai Phuong Thi Bach, Van Vu Kim, The Anh Pham, Duc Huy Tran, Trinh Ngoc An Le, Truong Vinh Ngoc Pham, Minh Triet Le, Dac Ho Vo, Thi Minh Thu Tran, Minh Nguyen Nguyen, Thi Tuong Vi Van, Anh Nhu Nguyen, Thi Trang Tran, Vu Uyen Tran, Minh Phong Le, Thi Thanh Do, Thi Van Phan, Luu Hong Dang Nguyen, Duy Sinh Nguyen, Van Thinh Cao, Thanh Thuy Thi Do, Dinh Kiet Truong, Hung Sang Tang, Hoa Giang, Hoai Nghia Nguyen, Minh Duy Phan, and Le Son Tran

Abstract

Despite their promise, circulating tumor DNA (ctDNA)-based assays for multi-cancer early detection face challenges in test performance, due mostly to the limited abundance of ctDNA and its inherent variability. To address these challenges, published assays to date demanded a very high-depth sequencing, resulting in an elevated price of test. Herein, we developed a multimodal assay called SPOT-MAS (Screening for the Presence Of Tumor by Methylation And Size) to simultaneously profile methylomics, fragmentomics, copy number, and end motifs in a single workflow using targeted and shallow genome-wide sequencing (∼0.55X) of cell-free DNA. We applied SPOT-MAS to 738 nonmetastatic patients with breast, colorectal, gastric, lung and liver cancer, and 1,550 healthy controls. We then employed machine learning to extract multiple cancer and tissue-specific signatures for detecting and locating cancer. SPOT-MAS successfully detected the five cancer types with a sensitivity of 72.4% at 97.0% specificity. The sensitivities for detecting early-stage cancers were 62.3% and 73.9% for stage I and II, respectively, increasing to 88.3% for nonmetastatic stage IIIA. For tumor-of-origin, our assay achieved an accuracy of 0.7. Our study demonstrates comparable performance to other ctDNA-based assays while requiring significantly lower sequencing depth, making it economically feasible for population-wide screening.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results